p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

Phase 1

Completed

Conditions: Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

Interventions: Drug: APR-246
Drug: Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

Brief Summary: The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and carboplatin/PLD chemotherapy regimen, compared with carboplatin/PLD chemotherapy regimen alone, in patients with platinum sensitive recurrent high grade serous ovarian cancer (HGSOC) with mutated p53. In addition, the study aims to assess the safety profile of the combined APR-246 and carboplatin/PLD chemotherapy regimen compared with carboplatin/PLD chemotherapy regimen alone, to evaluate potential biomarkers, and to assess the biological activity in tumor and surrogate tissues. The trial will enroll up to a maximum of 400 patients.

Recruitment & Eligibility

Inclusion Criteria

Confirmed High Grade Serous Ovarian Cancer, and positive nuclear immunohistochemical (IHC) staining for p53
Disease Progression between 6-24 months after a first or second platinum based regimen
At least a single measurable lesion. Phase II patients only
Adequate organ function prior to registration
Toxicities from previous cancer therapies must have recovered to grade 1 (defined by Common Terminology Criteria for Adverse Events [CTCAE] 4.0) Chronic stable grade 2 peripheral neuropathy secondary to neurotoxicity from prior therapies may be considered on a case by case basis
ECOG performance status of 0 to 1

Exclusion Criteria

Prior exposure to cumulative doses of doxorubicin >400 mg/m2 or epirubicin >720 mg/m2
History of allergic reactions to carboplatin, platinum containing compounds or mannitol and/or hypersensitivity to PLD or to any of the excipients
Unable to undergo imaging by either CT scan or MRI
Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment related complications
Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ)
Is taking concurrent (or within 4 week prior to registration) chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy that is considered to be investigational (i.e., used for non-approved indications(s) and in the context of a research investigation). Supportive care measures are allowed

Arm && Interventions

Group	Intervention	Description
Phase Ib. APR-246 (35mg/kg) + Carboplatin/PLD.	APR-246	Dose escalation of APR-246.
Phase Ib. APR-246 (35mg/kg) + Carboplatin/PLD.	Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)	Dose escalation of APR-246.
Phase II: Arm A. APR-246 + Carboplatin/PLD.	APR-246	Experimental
Phase II: Arm A. APR-246 + Carboplatin/PLD.	Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)	Experimental
Phase II: Arm B. Carboplatin/PLD.	Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)	Active Comparator
Phase Ib. APR-246 (50mg/kg) + Carboplatin/PLD.	APR-246	Dose escalation of APR-246.
Phase Ib. APR-246 (50mg/kg) + Carboplatin/PLD.	Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)	Dose escalation of APR-246.
Phase Ib. APR-246 (67.5mg/kg) + Carboplatin/PLD.	APR-246	Dose escalation of APR-246.
Phase Ib. APR-246 (67.5mg/kg) + Carboplatin/PLD.	Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)	Dose escalation of APR-246.

Primary Outcome Measures

Name	Time	Method
Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD Regimen	Until the end of the first treatment cycle, i.e., Day 28	DLT: Hematological and non-hematological toxicities according to grade/days stated in the protocol.
Phase Ib and II: Progression Free Survival (PFS)	Up to 24 months	Phase Ib: Progression-free Survival is calculated from date of enrollment to the date of disease progression or death due to any cause, whichever occurs first. Symptomatic deterioration is not considered PD. For a patient without evidence of disease progression or death, Progression-free survival will be censored at the date of last evaluable tumor assessment. Patients with no evaluable tumor assessments will be censored at the date of first study drug administration. Phase II: Progression-free survival (PFS) based on Blinded Independent Central Review (BICR) is the primary endpoint and is defined as the number of days from the date of randomization to the date of objective disease progression or relapse (according to RECIST v1.1 only) or death due to any cause, whichever occurs first. If neither event occurs, PFS is censored at the date of the last evaluable tumor assessment. Symptomatic deterioration is not considered objective disease progression.

Secondary Outcome Measures

Name	Time	Method
Phase Ib and Phase II: Overall Response Rate (RR)	Up to 24 months	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Locations (55): UCLA
🇺🇸
Los Angeles, California, United States
University of Chicago
🇺🇸
Chicago, Illinois, United States
Massachusetts General Hospital
🇺🇸
Boston, Massachusetts, United States
Dana Farber Cancer Institute
🇺🇸
Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Institute
🇺🇸
Detroit, Michigan, United States
Oregon Health & Science University
🇺🇸
Portland, Oregon, United States
The University of Pennsylvania
🇺🇸
Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center
🇺🇸
Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center, Magee-Womens Hospital
🇺🇸
Pittsburgh, Pennsylvania, United States
Vanderbilt University Medical Center
🇺🇸
Nashville, Tennessee, United States
Scroll for more (45 remaining)
UCLA
🇺🇸Los Angeles, California, United States